Page last updated: 2024-08-26

fulvestrant and toremifene

fulvestrant has been researched along with toremifene in 21 studies

Research

Studies (21)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	8 (38.10)	18.2507
2000's	6 (28.57)	29.6817
2010's	5 (23.81)	24.3611
2020's	2 (9.52)	2.80

Authors

Authors	Studies
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H	1
Balogh, I; Kim, HY; Koczok, K; Korade, Z; Liu, W; Mirnics, K; Porter, NA; Tallman, KA; Xu, L	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Gradishar, WJ; Jordan, VC	1
Belanger, A; Gauthier, S; Labrie, C; Labrie, F; Merand, Y; Poirier, D; Sanchez, R; Simard, J; Singh, SM	1
Bélanger, A; Candas, B; Gauthier, S; Labrie, C; Labrie, F; Li, X; Martel, C; Mérand, Y; Provencher, L	1
Anderson, KC; Chauhan, D; Ogata, A; Teoh, G; Treon, SP; Urashima, M; Webb, IJ	1
Assikis, VJ; Bilimoria, MM; Chatterton, R; Cisneros, A; Dragan, YP; England, GM; Jordan, VC; MacGregor, JI; Muenzner, HD; O'Regan, RM; Piette, M; Pitot, HC	1
DeGregorio, MW	1
Williams, GM	1
Ellmén, J; Kaukonen, M; Mäenpää, J; Pasanen, T	1
De Los Reyes, A; England, G; Jordan, VC; Lee, ES; O'Regan, RM; Schafer, JM; Yao, K	1
Barrett, JC; Kanai, H; Metzler, M; Tsutsui, T	1
Eckhardt, S	1
Cheng, JS; Ezaki, K; Kawashima, H; Kurisu, T; Nakatani, T; Sugita, S; Tanaka, T	1
Dahllund, J; Härkönen, P; Heiskanen, KM; Kallio, A; Zheng, A	1
Komm, BS; Pickar, JH	1
Blanco-Vaca, F; Dávalos, A; Escolà-Gil, JC; Fernández-Suárez, ME; Gómez-Coronado, D; Lasunción, MA; Martínez-Botas, J; Pastor, O	1
Chaiyakunapruk, N; Imanaka, Y; Kunisawa, S; Lertjanyakun, V	1
Guan, X; Li, C; Li, H; Li, L; Liu, B; Ma, F; Qian, H; Rong, G; Sun, X; Wang, W; Xu, B; Yi, Z; Zhai, J	1
Cai, R; Li, Q; Luo, Y; Ma, F; Mo, H; Wang, J; Xu, B; Yuan, P; Zhang, P	1

Reviews

4 review(s) available for fulvestrant and toremifene

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
Clinical potential of new antiestrogens. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:2 Topics: Antineoplastic Agents, Hormonal; Bone Density; Drugs, Investigational; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Osteoporosis, Postmenopausal; Piperidines; Raloxifene Hydrochloride; Tamoxifen; Toremifene	1997
[Perspectives for the hormonal therapy of breast cancer]. Magyar onkologia, 2003, Volume: 47, Issue:2 Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Letrozole; Nitriles; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Toremifene; Triazoles	2003
Selective estrogen receptor modulators and the combination therapy conjugated estrogens/bazedoxifene: A review of effects on the breast. Post reproductive health, 2015, Volume: 21, Issue:3 Topics: Animals; Breast; Breast Neoplasms; Drug Therapy, Combination; Estradiol; Estrogen Antagonists; Estrogens; Estrogens, Conjugated (USP); Female; Fulvestrant; Humans; Indoles; Osteoporosis; Postmenopause; Protective Factors; Raloxifene Hydrochloride; Risk Assessment; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene	2015

Other Studies

17 other study(ies) available for fulvestrant and toremifene

Article	Year
Identifying off-target effects and hidden phenotypes of drugs in human cells. Nature chemical biology, 2006, Volume: 2, Issue:6 Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship	2006
The Effect of Small Molecules on Sterol Homeostasis: Measuring 7-Dehydrocholesterol in Dhcr7-Deficient Neuro2a Cells and Human Fibroblasts. Journal of medicinal chemistry, 2016, Feb-11, Volume: 59, Issue:3 Topics: Animals; Cell Line; Dehydrocholesterols; Dose-Response Relationship, Drug; Fibroblasts; Homeostasis; Humans; Mice; Molecular Conformation; Neurons; Oxidoreductases Acting on CH-CH Group Donors; Small Molecule Libraries; Sterols; Structure-Activity Relationship	2016
Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer research, 1997, Aug-15, Volume: 57, Issue:16 Topics: Adenocarcinoma; Alkaline Phosphatase; Benzopyrans; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Proteins; Piperidines; Propionates; Raloxifene Hydrochloride; Tamoxifen; Toremifene; Tumor Cells, Cultured	1997
Comparison of the effects of the new orally active antiestrogen EM-800 with ICI 182 780 and toremifene on estrogen-sensitive parameters in the ovariectomized mouse. Endocrinology, 1998, Volume: 139, Issue:5 Topics: Animals; Benzopyrans; Estradiol; Estrogen Antagonists; Estrogens; Estrone; Female; Fulvestrant; Mice; Mice, Inbred BALB C; Organ Size; Ovariectomy; Propionates; Receptors, Estrogen; Toremifene; Uterus; Vagina	1998
Anti-estrogens induce apoptosis of multiple myeloma cells. Blood, 1998, Sep-01, Volume: 92, Issue:5 Topics: Apoptosis; Breast Neoplasms; Cell Division; Cell Survival; Coloring Agents; Estradiol; Estrogen Antagonists; Flow Cytometry; Fulvestrant; Hematopoietic Stem Cells; Humans; Immunoblotting; Multiple Myeloma; Propidium; Receptors, Estrogen; Tamoxifen; Toremifene; Tumor Cells, Cultured	1998
Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. Journal of the National Cancer Institute, 1998, Oct-21, Volume: 90, Issue:20 Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Models, Animal; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Mice; Mice, Nude; Ovariectomy; Tamoxifen; Toremifene	1998
Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. Journal of the National Cancer Institute, 1999, Mar-03, Volume: 91, Issue:5 Topics: Antineoplastic Agents, Hormonal; Cell Division; Endometrial Neoplasms; Endometrium; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Tamoxifen; Toremifene	1999
Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. Journal of the National Cancer Institute, 1999, Apr-21, Volume: 91, Issue:8 Topics: Animals; Antineoplastic Agents, Hormonal; Cell Transformation, Neoplastic; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Mice; Neoplasms, Hormone-Dependent; Tamoxifen; Toremifene	1999
Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. Journal of the National Cancer Institute, 1999, Jun-02, Volume: 91, Issue:11 Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Risk; Tamoxifen; Toremifene	1999
Cross-resistance of triphenylethylene-type antiestrogens but not ICI 182,780 in tamoxifen-stimulated breast tumors grown in athymic mice. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:12 Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Estrogen Antagonists; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Stilbenes; Tamoxifen; Time Factors; Toremifene; Tumor Cells, Cultured	2000
Cell-transforming activity and estrogenicity of bisphenol-A and 4 of its analogs in mammalian cells. International journal of cancer, 2001, Jul-01, Volume: 93, Issue:1 Topics: Animals; Benzhydryl Compounds; Breast Neoplasms; Cell Division; Cell Transformation, Neoplastic; Cells, Cultured; Colony-Forming Units Assay; Diethylstilbestrol; Estradiol; Estrogen Antagonists; Estrogens, Non-Steroidal; Female; Fetus; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Molecular Structure; Phenols; Receptors, Progesterone; Reverse Transcriptase Polymerase Chain Reaction; Structure-Activity Relationship; Toremifene; Tumor Cells, Cultured	2001
Effect of anti-estrogens on the androgen receptor activity and cell proliferation in prostate cancer cells. Urological research, 2004, Volume: 32, Issue:6 Topics: Androgen Receptor Antagonists; Cell Line, Tumor; Cell Proliferation; Estradiol; Estrogen Antagonists; Fulvestrant; Humans; Male; Mutation; Prostatic Neoplasms; Receptors, Androgen; Selective Estrogen Receptor Modulators; Tamoxifen; Toremifene; Transcriptional Activation	2004
Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis : an international journal on programmed cell death, 2005, Volume: 10, Issue:6 Topics: Antineoplastic Agents, Hormonal; Apoptosis; Bongkrekic Acid; Breast Neoplasms; Caspase 9; Cell Line, Tumor; Cytochromes c; Drug Screening Assays, Antitumor; Enzyme Activation; Estradiol; Estrogens; Female; Fulvestrant; Humans; Membrane Potential, Mitochondrial; Mitochondria; Onium Compounds; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Tamoxifen; Toremifene	2005
Clinically used selective estrogen receptor modulators affect different steps of macrophage-specific reverse cholesterol transport. Scientific reports, 2016, 09-07, Volume: 6 Topics: Acetyl-CoA C-Acetyltransferase; Animals; Apolipoprotein A-I; ATP Binding Cassette Transporter 1; ATP Binding Cassette Transporter, Subfamily G; Biological Transport; Cholesterol; Cholesterol Esters; Diet, Western; Esterification; Estradiol; Feces; Fulvestrant; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Liver; Macrophages; Male; Mice; Mice, Inbred C57BL; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; THP-1 Cells; Toremifene	2016
Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan. PharmacoEconomics, 2018, Volume: 36, Issue:9 Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Everolimus; Female; Fulvestrant; Health Care Costs; Humans; Japan; Markov Chains; Middle Aged; Models, Economic; Postmenopause; Quality-Adjusted Life Years; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Toremifene	2018
Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers. Breast (Edinburgh, Scotland), 2020, Volume: 52 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; China; Circulating Tumor DNA; Everolimus; Female; Fulvestrant; Humans; Middle Aged; Progression-Free Survival; Retrospective Studies; Signal Transduction; Sirolimus; Tamoxifen; TOR Serine-Threonine Kinases; Toremifene	2020
Treatment patterns and clinical outcomes in patients with metastatic breast cancer treated with palbociclib-based therapies: real-world data in the Han population. Chinese medical journal, 2022, Jul-20, Volume: 135, Issue:14 Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Everolimus; Female; Fulvestrant; Humans; Letrozole; Piperazines; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Toremifene	2022